TrialBMC cancer2024

A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.

Qingyuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.